New drug combination for advanced HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (recurrent or metastatic) breast cancer that is HER2-positive
- You have received no more than one prior treatment regimen for advanced cancer
- You are in good overall health (ECOG performance status 0–1)
- Your heart, liver, and kidney function are adequate based on recent blood tests and heart imaging
- You have not had major surgery or significant trauma in the past 4 weeks
- You are not pregnant, not breastfeeding, and willing to use effective contraception if able to conceive
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
This trial tests a combination of two drugs that target HER2-positive breast cancer: trastuzumab deruxtecan (currently the standard) plus a newer drug called pyrotinib. The goal is to see if combining these drugs helps people whose cancer has continued to grow despite taking trastuzumab deruxtecan alone.
This trial tests whether adding the targeted drug pyrotinib to the standard HER2-targeted medicine trastuzumab after surgery can help lower the chance of early-stage HER2-positive breast cancer coming back.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) before surgery for women with early-stage HER2-positive breast cancer. The goal is to shrink the tumor and improve treatment outcomes.
This trial studies a combination of anti-cancer medicines (including trastuzumab and hormone therapy) for women with stage II–III breast cancer that is ER-, PR-, and HER2-positive. It aims to improve outcomes by attacking the cancer in different ways.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.